GLP-1 Solution

Provider Profile Name: GLP-1 Solution
Website: glp1solution.store
Provider Type: Direct-to-Consumer GLP-1 Website / Online Seller
Public Contact: sales@glp1solution.store
Public Address Listed in FDA Letter: 785 15h Street, Office 478, 81566 Berlin, Germany.

Operating Details

• Operate as a direct-to-consumer online seller rather than a standard telehealth platform.
• Unlike the telehealth providers in your other articles, the FDA letter does not describe GLP-1 Solution as a physician-led care model with provider consultations, insurance navigation, coaching, or ongoing clinical oversight. 
• Based on the public record available, the site is best understood as a direct online seller marketing GLP-1-related products to consumers.

Approach Public-facing details are limited, but the FDA’s review makes the site’s commercial approach clear: it marketed compounded GLP-1-related products directly through its website and used language the agency said was false or misleading. Specifically, the FDA cited website claims that implied its compounded products were the same as FDA-approved drugs, including use of the term “MOUNJARO” and the statement that semaglutide is “the generic drug delivered in Ozempic, Rybelsus, and Wegovy.” 

That matters because compounded drugs are not FDA-approved, and the FDA said these marketing claims misbranded the products by implying equivalence to approved branded medications when that had not been established. 

About the Company

There is very little transparent public company information available for GLP-1 Solution beyond what appears in the FDA warning letter and public website traces. The clearest independently verifiable event in the company’s public record is the FDA warning letter issued on September 9, 2025. In that letter, the FDA said GLP-1 Solution’s compounded retatrutide products were unapproved new drugs and misbranded drugs under the Federal Food, Drug, and Cosmetic Act. 

The FDA also said GLP-1 Solution’s marketing of compounded semaglutide and tirzepatide was false or misleading. In addition, the agency stated that if the company did not adequately address the cited violations, FDA could pursue legal action, including seizure or injunction, and warned that products appearing to be misbranded or unapproved new drugs could be detained or refused admission into the United States. 

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

A separate current FDA consumer safety page also warns the public not to purchase unapproved GLP-1 drugs sold directly to consumers, including products falsely labeled “for research purposes” or otherwise marketed outside approved channels, because such products may be of unknown quality and harmful. 

GLP-1 Offerings and Weight Loss Services

Based on the FDA’s review, GLP-1 Solution offered:

• Compounded retatrutide
• Compounded semaglutide
• Compounded tirzepatide

The most serious issue in the letter concerned retatrutide. FDA said compounded drug products using retatrutide do not qualify for the exemptions under sections 503A or 503B because retatrutide is not the subject of an applicable USP/NF monograph, is not a component of an FDA-approved human drug, and does not appear on the relevant bulks lists. FDA therefore treated those retatrutide products as unapproved new drugs and misbranded drugs.

For semaglutide and tirzepatide, FDA’s concern in this letter centered on marketing claims rather than a blanket statement identical to the retatrutide section. The agency specifically objected to language that implied the products were generic or equivalent versions of approved drugs.

Pricing — and What Reviewers Say

No pricing data is publicly available for GLP-1 Solution. The directory pricing snapshot contains no numeric rows for monthly membership, medication cost, or total out-of-pocket estimates. No user-reported prices have been submitted to the directory at time of writing.

Without pricing information, it is not possible to benchmark GLP-1 Solution against the broader market. For context, the compounded GLP-1 telehealth market typically runs $149–$299/month for semaglutide and $249–$399/month for tirzepatide when all-inclusive. Brand-name options without insurance run significantly higher — Wegovy lists at approximately $1,300–$1,500/month and Zepbound at approximately $1,086/month at retail. Patients should obtain a full cost disclosure from GLP-1 Solution, including whether the quoted price covers the consultation, medication, supplies, and shipping, before proceeding.

Reviews from Trustpilot and Google

No meaningful independent review pool was identified for GLP-1 Solution during this research. There is not a clearly established Trustpilot company profile or a verified Google Business review base comparable to mainstream telehealth providers. As a result, there is not enough independent consumer-review evidence to assess shipping reliability, billing practices, support responsiveness, or real-world outcomes.

Compounding Pharmacies Used

There is not any public disclosure naming licensed 503A or 503B pharmacy partners for GLP-1 Solution. The FDA letter addresses GLP-1 Solution directly and discusses compounded products sold through the site, but it does not identify a pharmacy partner by name.

That lack of public pharmacy transparency is important. In legitimate telehealth workflows, patients should be able to identify the licensed pharmacy fulfilling a prescription and verify whether it operates under appropriate regulatory standards. In GLP-1 Solution’s case, that information was not clearly available in the public sources I could verify.

Editor’s Note: GLP-1 Solution is not presented here as a standard telehealth provider. The most important fact about this website is that the FDA issued it a warning letter on September 9, 2025 after reviewing the site and concluding that its compounded retatrutide products were unapproved new drugs and misbranded, and that its promotional claims for compounded semaglutide and tirzepatide were false or misleading.